Vivani Medical Inc (VANI)
Vivani Medical Inc is a clinical-stage biopharmaceutical company listed on the NASDAQ under the symbol VANI. The company is developing miniaturized subdermal drug-implant technologies designed to support treatment of chronic diseases and address medication non-adherence. Its NanoPortal platform underpins a pipeline that includes NPM-115, a high-dose exenatide implant candidate in clinical development for chronic weight management in people with obesity or overweight; NPM-119, an exenatide implant candidate in preclinical development for type 2 diabetes; NPM-139, a small GLP-1 implant for weight management; and OKV-119, an exenatide implant being developed for metabolic disease in cats. Vivani Medical is headquartered in Alameda, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VANI
|
$0.93
|
-26.8% Downside
|
Overvalued
|
$3.83
|
201.8% Upside
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
5.9x
|
114.6 M
|
109.8 M
|
13.8%
|
43.1%
|
-4.2
|
100.7%
|